Dr. Airriess has a long history of connecting business and science in the development of medtech and biotech solutions. As CEO of Cortechs.ai he drives strategic development of the company that pioneered the application of volumetric MRI to routine clinical practice. Over the past 12 years, Cortechs.ai’ flagship volumetric MRI product, NeuroQuant, has been the go-to application for fast, objective volumetric analysis of neurodegenerative conditions such as Alzheimer’s, multiple sclerosis, epilepsy, and traumatic brain injury.

Previously, as chief operating officer of California Stem Cell (acquired by Caladrius Biosciences), Dr. Airriess drove company development from start-up to the clinical development phase of several therapeutic candidates, including FDA approval to begin a Phase III clinical trial using autologous stem cells to treat metastatic melanoma.

Other positions held include assistant professor at the University of British Columbia, Canada, and director of scientific computing for the National Center for Microscopy and Imaging Research and the Biomedical Informatics Research Network, both headquartered at the University of California, San Diego. Dr. Airriess has a Ph.D. in cardiovascular physiology and was a post-doctoral fellow at the University of Cambridge, UK and the University of Sydney, Australia.

Dr. White brings over 15 years of experience developing and commercializing advanced MRI and CT diagnostic imaging technologies. Before joining Cortechs.ai, Nate was co-founder and CEO of HealthLytix – a healthcare technology startup applying genetics and medical imaging AI for early cancer detection (acquired by Cortechs.ai). While at HealthLytix, he rapidly grew the business to introduce two FDA-cleared software applications into the marketplace within its short two-year history. Prior to HealthLytix, Nate was Assistant Professor of Radiology and Director of Imaging Technology at the Center for Translational Imaging and Precision Medicine at the University of California, San Diego, where he invented several MRI technologies that were subsequently licensed and commercialized by GE Healthcare. In addition, Nate co-invented a novel non-invasive MRI technique for cancer imaging called Restriction Spectrum Imaging MRI (RSI-MRI), which now serves as the basis for Cortechs.ai’s oncology imaging platform. Nate is a passionate and experienced technology leader and serial entrepreneur with degree’s in both Biomedical Engineering and Cognitive Science. Nate has authored more than 40 peer-reviewed publications and holds five patents.

Mr. Cohen brings over 12 years of proven commercial sales and leadership success.  With expertise in business development and sales strategies in both large hospital health systems and outside the hospital space, Mr. Cohen has a deep focus on integrated radiology solutions, informatics, and artificial intelligence to help healthcare providers deliver improved outcomes at a lower cost. Prior to joining Cortechs.ai he served as the business manager of western North America at Philips Healthcare in the Precision Diagnosis sector. He also was the vice president of sales at Shared Imaging and director of sales and marketing at Desert Valley Radiology. Notable achievements include over 500 million in total sales attainment, multiple sales performance awards, and graduating from Horizon’s Leadership Program.

Ms. Marinkovic is responsible for Quality Assurance and ensuring regulatory compliance to government and industry standards. Prior to assuming this position, she was Cortechs.ai’s Director of Sales and Marketing, where she also served as the Quality Assurance Manager. Ms. Marinkovic holds a master’s degree in business administration from the University of La Verne and a bachelor’s degree in sociology from the University of Zagreb. She also holds a professional certificate in regulatory affairs from the University of California, San Diego.

Dr. Brewer is the Chief Medical Advisor of Cortechs.ai and was the first physician to incorporate NeuroQuant® into clinical practice. He assisted in the design of the NeuroQuant reports and in the studies that led to NeuroQuant’s FDA clearance.

Dr. Brewer received his M.D. and Ph.D. at Stanford Medical School. There, he used advanced structural and functional neuroimaging approaches to examine the role of the hippocampus in forming and retrieving memories. He completed his neurology residency training at Johns Hopkins. Afterward, he joined the faculty of the University of California, San Diego, where he has a joint appointment in Radiology and Neurosciences.

Dr. Brewer sees patients at the University of California, San Diego and the Veterans Affairs Hospital in La Jolla. He directs the Imaging Core for the multi-institutional Alzheimer’s Disease Cooperative Study and oversees the imaging of all enrolled subjects at the Shiley-Marcos Alzheimer’s Disease Research Center.

Dr. Bash is the Medical Director of Neuroradiology at San Fernando Valley Interventional Radiology, which is part of the RadNet enterprise.  Dr. Bash joined RadNet in 2005.  Prior to this, she was on the faculty at UCLA as an Assistant Professor of Neuroradiology, after completing a two-year Neuroradiology Fellowship at UCLA and Radiology Residency also at UCLA.

During her tenure at UCLA, Dr. Bash was the recipient of the Issa Yaghmai Scholarship for best paper published in a peer-reviewed journal; Consultant of the Year Award, issued by the Emergency Department to one UCLA resident a year; as well as the Outstanding Resident Award, issued by Olive View-UCLA to one resident a year.  Dr. Bash was awarded James Scholar Honors during her medical school years at the University of Illinois, which recognizes a medical student with extraordinary ability and achievement.

Dr. Bash’s passion and interests lie in Artificial Intelligence applications in Neuroimaging and other advanced Neuroimaging techniques which add patient-centric value and quality.

Dr. Mazhari is a Board Certified Neurologist, and Neuroimager at Dent Neurologic Institute, in Amherst, New York. He serves as Director of Dent MS Center, with 15+ years of experience and instrumental to developing a CMSC Certified MS Center, as well as the only National MS Society Certified Comprehensive Care Partner in Western NY State. He also serves as Co-founder of the Dent Spasticity Clinic.

He continues to serve as neuroimager with the Dent Neuroimaging Center, and prior to that he was Director of Advanced MRI services of Neurology and Neuroscience Associates, and for Unity Network Neurology in Northeastern Ohio.

He has served as faculty and board member for American Society of Neuroimaging, American Academy of Neurology neuroimaging section, and Asked the Expert series at ECTRIMS, as well as other national and international meetings.

Dr. Mazhari has also served as consultant, advisory board member and faculty for various biopharmaceutical and device companies, and is actively involved in clinical research trials as main or principal investigator in multiple sclerosis as well as other neurological disease states.

Tyler Seibert MD, PhD, is a physician-scientist and engineer with substantial experience in complex data analysis, including development, validation, and translation of novel methods in both biomedical imaging and genetics. Clinically, he is a board-certified radiation oncologist and sub-specialize in the treatment of aggressive prostate cancer.  Over his career he has prioritized research to improve precision screening, detection, and treatment of prostate cancer through quantitative engineering.

Seibert started over 18 years ago in quantitative and advanced MRI research. He has designed and conducted many imaging experiments, actively participating in imaging protocol design, patient recruitment, data collection, image analysis, and peer-reviewed publication. Nearly all of his recent work has focused on imaging of tumors and radiation effects in patients with cancer.

Dr. Jeff Rudie MD, PhD, is a board certified diagnostic radiologist, specializing Emergency and Neuroradiology. His research is focused on developing artificial intelligence tools that can be integrated into the clinical workflow to improve the accuracy and efficiency of neuroradiology. He also has been involved in organizing the radiology artificial intelligence challenges, including the RSNA/ASNR/BraTS multimodal brain tumor segmentation challenge.

Dr. Rudie completed a combined MD PhD program in 2014. His PhD in neuroscience focused on combining genetics with functional and structural neuroimaging to better understand autism spectrum disorders. As a radiology resident his research interests became more translational, which included developing pipelines for fully automated diagnosis of brain MRIs. As a neuroradiology fellow he developed algorithms for automated segmentation and longitudinal assessment of diffuse gliomas and intracranial metastases.

Dr. Airriess has a long history of connecting business and science in the development of medtech and biotech solutions. As CEO of Cortechs.ai he drives strategic development of the company that pioneered the application of volumetric MRI to routine clinical practice. Over the past 12 years, Cortechs.ai’ flagship volumetric MRI product, NeuroQuant, has been the go-to application for fast, objective volumetric analysis of neurodegenerative conditions such as Alzheimer’s, multiple sclerosis, epilepsy, and traumatic brain injury.

Previously, as chief operating officer of California Stem Cell (acquired by Caladrius Biosciences), Dr. Airriess drove company development from start-up to the clinical development phase of several therapeutic candidates, including FDA approval to begin a Phase III clinical trial using autologous stem cells to treat metastatic melanoma.

Other positions held include assistant professor at the University of British Columbia, Canada, and director of scientific computing for the National Center for Microscopy and Imaging Research and the Biomedical Informatics Research Network, both headquartered at the University of California, San Diego. Dr. Airriess has a Ph.D. in cardiovascular physiology and was a post-doctoral fellow at the University of Cambridge, UK and the University of Sydney, Australia.

Dr. White brings over 15 years of experience developing and commercializing advanced MRI and CT diagnostic imaging technologies. Before joining Cortechs.ai, Nate was co-founder and CEO of HealthLytix – a healthcare technology startup applying genetics and medical imaging AI for early cancer detection (acquired by Cortechs.ai). While at HealthLytix, he rapidly grew the business to introduce two FDA-cleared software applications into the marketplace within its short two-year history. Prior to HealthLytix, Nate was Assistant Professor of Radiology and Director of Imaging Technology at the Center for Translational Imaging and Precision Medicine at the University of California, San Diego, where he invented several MRI technologies that were subsequently licensed and commercialized by GE Healthcare. In addition, Nate co-invented a novel non-invasive MRI technique for cancer imaging called Restriction Spectrum Imaging MRI (RSI-MRI), which now serves as the basis for Cortechs.ai’s oncology imaging platform. Nate is a passionate and experienced technology leader and serial entrepreneur with degree’s in both Biomedical Engineering and Cognitive Science. Nate has authored more than 40 peer-reviewed publications and holds five patents.

Dr. Dale is a computational neuroscientist with extensive experience in multimodal neuroimaging methods. He played a key role in the development of functional neuroimaging methods, including event-related fMRI, and multimodal integration of MEG/EEG, fMRI, and structural imaging data.

Dr. Dale is currently the founding Co-Director of the Multimodal Imaging Laboratory, an interdisciplinary imitative of the Departments of Neurosciences and Radiology at the University of California, San Diego. He holds a Bachelor’s degree in Computer Science from the University of Texas and studied at Harvard and MIT on a Fulbright Fellowship.

From Harvard, he received a Master’s degree in Engineering Science. Dr. Dale earned his Ph.D. from the University of California, San Diego, where he began working on the development of accurate and automated algorithms for head segmentation.

Paul J. Mirabella is the President and CEO of Paul J. Mirabella, Investments and Consulting, LLC. Paul has worked as a senior executive in the healthcare industry for over 40 years. He is actively involved in imaging solutions to reduce radiation as well as artificial intelligence applications largely in cardiology and neurology. He was formerly the President and CEO of GE Healthcare Global Diagnostic Imaging Business, the Americas Region and the Global Services Business. More recently, he was a key investor in and Chairman & CEO of Naviscan, Inc. a high resolution, organ specific PET scanner.

He holds an BS in Aerospace Engineering and Applied Mechanics for the Polytechnic Institute of Brooklyn (now NYU) and an MS in Mechanical Engineering from the University of Central Florida. He held four of the original patents in CT. He is involved in consulting for Private Equity, Venture Capital firms and a variety of healthcare businesses. He is also a limited partner and investor in entities ranging from venture capital companies, contract manufacturing, oil and gas development and industrial real estate. He has been a guest lecturer on leadership at the UCSD Rady School of Management.

Currently, Kong Han Tan holds the position of President, COO & Executive Director at Genting Bhd. and Chief Executive Officer & Executive Director at Genting Plantations Bhd. (a subsidiary of Genting Bhd.).

He is also Chief Executive Officer & Executive Director at Genting Plantations Bhd., Member of Malaysian Bar Association, Member of The Honourable Society of Lincoln’s Inn, Administrator at The Community Chest of Malaysia and Managing Director at Pan Malaysian Pools Sdn. Bhd. and on the board of 8 other companies.

In his past career, Mr. Tan was Group Chief Operating Officer for Tanjong Plc. He received a graduate degree from the University of Cambridge.